Dyadic International stock faces Nasdaq compliance tests by March 2027

Published on 09/30/2026 at 11:51 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Dyadic International stock faces Nasdaq tests requiring a USD 1.00 bid price and USD 35.0 million market value by March 24, 2027. Q2 revenue was USD 961,138.

DYAI, US26746E1055, Illustration mit AI erstellt.

Dyadic International (ISIN US26746E1055) faces two Nasdaq compliance tests after notices dated September 25, 2026. StockTitan reports that the company must restore a USD 1.00 closing bid price and a USD 35.0 million market value of listed securities by March 24, 2027, with each measure required for 10 consecutive business days.

Nasdaq tests set a hard deadline

The notices concern Nasdaq Listing Rules 5550(a)(2) and 5550(b). The Nasdaq Capital Market listing remains in place while Dyadic evaluates its response, but the two thresholds create a clear financial and market-value benchmark for the next six months.

Dyadic's market capitalization stood at USD 17.0 million on September 29, 2026. That level is below the USD 35.0 million listing threshold cited in the filing summary, making market value the larger numerical gap alongside the bid-price requirement.

Revenue remains grant-heavy

For the quarter ended June 30, 2026, total revenue was USD 961,138, down 0.57 percent from USD 966,630 a year earlier, while net loss reached USD 2,123,884, or USD 0.06 per share. StockTitan said grant revenue contributed USD 837,252 of the quarterly total.

The same filing summary reported USD 4,794,798 in cash, cash equivalents, restricted cash and investment-grade securities as of June 30, 2026, down from USD 8,587,289 on December 31, 2025. Total liabilities reached USD 8,923,775, against a stockholders' equity deficit of USD 2,387,244.

Commercial execution becomes central

At the Lytham Partners Fall 2026 Investor Conference on September 29, 2026, management described a shift from platform development toward commercial execution. Investing.com reported that Dyadic now has products in market, multiple revenue streams and partner-led distribution across life sciences, food nutrition and bioindustrial applications.

The commercial transition matters because recurring product sales could strengthen revenue quality, while the June 30 balance sheet shows the pressure created by ongoing losses and limited liquidity. Dyadic is therefore balancing expansion of its C1 and Dapibus platforms against the immediate Nasdaq tests.

Market value remains the key hurdle

Dyadic's USD 17.0 million market capitalization on September 29, 2026 provides the clearest numerical measure of the listing challenge. The March 24, 2027 deadline now gives the company a defined period to improve both its share-price level and its listed market value.